by sfrazee | Apr 25, 2024 | White Papers
The rapid emergence of vaccines and therapeutics in response to the onset of the coronavirus (COVID-19) pandemic demonstrated the value of medical innovation. These advances not only led to enhanced patient welfare by reducing the disease’s mortality and morbidity but...
by cmicklin | Feb 15, 2024 | White Papers
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
by susuguo | Feb 1, 2024 | White Papers
Price theory says that the most important effects of policy and technological change are often found beyond their first point of contact. This appears opposed to econometric methods that rule out spillovers of one person’s treatment on another’s outcomes. This paper...
by mheinl | Nov 29, 2023 | Uncategorized, White Papers
Expediting breakthrough medical device reimbursement has become a recent public policy issue. This paper provides evidence of the value of faster reimbursement of new medical devices using a comprehensive dataset of past approved devices. The estimation considers the...
by mheinl | Oct 9, 2023 | White Papers
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
by susuguo | Sep 1, 2023 | White Papers
Proposed “delinking” legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they negotiate for drug insurance plans serving Medicare beneficiaries. This policy would significantly change drug pricing and...
